WO1991002786A1 - Transportmedium für mikroorganismen - Google Patents
Transportmedium für mikroorganismen Download PDFInfo
- Publication number
- WO1991002786A1 WO1991002786A1 PCT/EP1989/001003 EP8901003W WO9102786A1 WO 1991002786 A1 WO1991002786 A1 WO 1991002786A1 EP 8901003 W EP8901003 W EP 8901003W WO 9102786 A1 WO9102786 A1 WO 9102786A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sodium
- chloride
- transport
- transport medium
- agar
- Prior art date
Links
- 239000006163 transport media Substances 0.000 title claims abstract description 19
- 244000005700 microbiome Species 0.000 title claims abstract description 6
- 239000000203 mixture Substances 0.000 claims abstract description 18
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims abstract description 14
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 12
- 229920001817 Agar Polymers 0.000 claims abstract description 11
- 239000008272 agar Substances 0.000 claims abstract description 11
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 7
- 239000001110 calcium chloride Substances 0.000 claims abstract description 7
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 7
- 229910001629 magnesium chloride Inorganic materials 0.000 claims abstract description 7
- 235000013372 meat Nutrition 0.000 claims abstract description 7
- 239000001103 potassium chloride Substances 0.000 claims abstract description 7
- 239000011780 sodium chloride Substances 0.000 claims abstract description 7
- 239000011734 sodium Substances 0.000 claims abstract description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 5
- 235000011164 potassium chloride Nutrition 0.000 claims abstract description 5
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000007789 gas Substances 0.000 claims description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 6
- 230000001681 protective effect Effects 0.000 claims description 6
- GEKBIENFFVFKRG-UHFFFAOYSA-L disodium;2,3-dihydroxypropyl phosphate Chemical compound [Na+].[Na+].OCC(O)COP([O-])([O-])=O GEKBIENFFVFKRG-UHFFFAOYSA-L 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 3
- 239000001569 carbon dioxide Substances 0.000 claims description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 3
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 3
- 230000003647 oxidation Effects 0.000 claims description 3
- 238000007254 oxidation reaction Methods 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 abstract description 7
- 239000002609 medium Substances 0.000 abstract description 4
- 241000192125 Firmicutes Species 0.000 abstract description 2
- QMIDDQFZXOSYIL-UHFFFAOYSA-K [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O.OCC(O)CO Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O.OCC(O)CO QMIDDQFZXOSYIL-UHFFFAOYSA-K 0.000 abstract description 2
- 244000052769 pathogen Species 0.000 description 12
- 241001153886 Ami Species 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000000721 bacterilogical effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- GNBVPFITFYNRCN-UHFFFAOYSA-M sodium thioglycolate Chemical compound [Na+].[O-]C(=O)CS GNBVPFITFYNRCN-UHFFFAOYSA-M 0.000 description 2
- 229940046307 sodium thioglycolate Drugs 0.000 description 2
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000002824 redox indicator Substances 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000012859 sterile filling Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/04—Preserving or maintaining viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
Definitions
- the present invention relates to a new transport medium for microorganisms, in particular gram-negative, gram-positive and anaerobic bacteria.
- the known transport media have proven to be quite useful for a normal transport time of about 12-24 hours and for aerobic and less sensitive anaerobic bacteria. With longer transport times of 48-72 hours as they can occur in unfavorable traffic conditions or on weekends and for
- the task was therefore to find new transport media in which particularly sensitive pathogens can be kept in a reproductive state for a long time.
- composition of the agent according to the invention has strong similarities to the known transport medium from Amies, which also contains agar, sodium, potassium, calcium and magnesium chloride and sodium thioglucolate, but the sodium phosphate buffer from Amies is replaced by a sodium glycerol phosphate buffer and additionally the mixture enriched with meat extract.
- the new medium has a slightly reduced content due to the content of thioglucolate, so that in particular in connection with an oxygen-free protection containing nitrogen or carbon dioxide gas atmosphere, anaerobic bacteria are particularly protected.
- the addition of meat extract causes a weak supply of nutrients, which obviously favors the persistence of the pathogens, but without growth and initiate an increase.
- agar serves as a gel-forming agent in order to give the mixture the necessary strength. Quantities of 2-10 g / l are useful for this purpose, 5 g / 1 are preferred.
- Sodium thioglucolate and sodium glycerol phosphate in turn serve on the one hand to make the mixture weakly reducing, which, as stated above, favors the anaerobic pathogens in particular, and on the other hand the pH value of the mixture of approx. 7.3 + 0, which is important for the viability of the bacteria, 1 to hold or adjust.
- the mixture according to the invention is excellently suitable for the production of prefabricated transport containers which, if appropriate, are filled with sterile filling of the mixture into the usual transport tubes and vials and with a moisture-proof closure in a protective gas atmosphere and storage at normal temperatures between 6 and 20 ° C are still fully usable after 6-12 months.
- the invention can be any suitable material. Depending on the intended purpose, the invention can be any suitable material.
- Redox indicator can be added, such as methylene blue or resazurin, which shows through its discoloration whether the protective gas atmosphere is optionally mixed with oxygen.
- Redox indicator can be added, such as methylene blue or resazurin, which shows through its discoloration whether the protective gas atmosphere is optionally mixed with oxygen.
- antimicrobial additives such as vancomycin, kanamycin, nystatin or trimethoprim.
- compositions according to the invention were compared against a commercial transport medium according to "Amies of the following composition: Agar no. 1 7.5
- the preservative properties of the two transport media were compared after periods of 24, 48, 72 and 96 hours against a representative number of different gram-positive, gram-negative and anaerobic bacteria.
- the results are summarized in the following table, where the results represent the mean values from a number of n samples.
- cultures the pathogen in physiological saline solution are brought to a concentration of 5-10,000 germs / ml and 0.1 ml of this reading is sprayed onto the agar surface of the transport bottle.
- the vials are each sealed with a rubber membrane and filled with a protective gas atmosphere for anaerobic bacteria.
- 0.1 ml of the mixture is removed from agar plates which are suitable for the microorganism in question, spread out and incubated at 37 °.
- the shelf life of the pathogens in the transport medium is assessed semi-quantitatively by evaluating the number of colonies in the classes: abundant (+++), moderate (++), isolated (+) and no germ growth (-).
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19883812194 DE3812194A1 (de) | 1988-04-13 | 1988-04-13 | Transportmedium fuer mikroorganismen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1991002786A1 true WO1991002786A1 (de) | 1991-03-07 |
Family
ID=6351840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP1989/001003 WO1991002786A1 (de) | 1988-04-13 | 1989-08-25 | Transportmedium für mikroorganismen |
Country Status (2)
| Country | Link |
|---|---|
| DE (1) | DE3812194A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) |
| WO (1) | WO1991002786A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0786663A1 (en) * | 1996-01-26 | 1997-07-30 | Kyowa Medex Co., Ltd. | Method for storing liquid diagnostic reagents |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0184019A1 (en) * | 1984-11-09 | 1986-06-11 | Hitachi, Ltd. | Thermostable alpha-amylase-producing, thermophilic anaerobic bacteria, thermostable alpha-amylase and process for producing the same |
| EP0255124A2 (en) * | 1986-07-29 | 1988-02-03 | Hitachi, Ltd. | Thermostable glucoamylase, a method for production of glucose using same and a plant for production thereof |
| EP0275901A2 (de) * | 1987-01-17 | 1988-07-27 | Hoechst Aktiengesellschaft | Verwendung von Gamma-Glutamyl-Transpeptidase |
-
1988
- 1988-04-13 DE DE19883812194 patent/DE3812194A1/de active Granted
-
1989
- 1989-08-25 WO PCT/EP1989/001003 patent/WO1991002786A1/de unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0184019A1 (en) * | 1984-11-09 | 1986-06-11 | Hitachi, Ltd. | Thermostable alpha-amylase-producing, thermophilic anaerobic bacteria, thermostable alpha-amylase and process for producing the same |
| EP0255124A2 (en) * | 1986-07-29 | 1988-02-03 | Hitachi, Ltd. | Thermostable glucoamylase, a method for production of glucose using same and a plant for production thereof |
| EP0275901A2 (de) * | 1987-01-17 | 1988-07-27 | Hoechst Aktiengesellschaft | Verwendung von Gamma-Glutamyl-Transpeptidase |
Non-Patent Citations (1)
| Title |
|---|
| DIALOG INFORMATION SERVICES, File 351, WORLD PATENT INDEX 81-90, Dialog Accession No. 89-316683/44, KLIETMANN W., "Agar Medium to Transport Microorganisms, Esp. Anaerobic Bacteria - Contg. Meat Extract, Salts, Reducing Agent and Sodium Glycerine Phosphate, Providing Long Term Viability"; & DE,A,3 812 194, 26-10-89, (Basic). * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0786663A1 (en) * | 1996-01-26 | 1997-07-30 | Kyowa Medex Co., Ltd. | Method for storing liquid diagnostic reagents |
| US5783382A (en) * | 1996-01-26 | 1998-07-21 | Kyowa Medex Co., Ltd. | Method for storing liquid diagnostic reagents |
Also Published As
| Publication number | Publication date |
|---|---|
| DE3812194A1 (de) | 1989-10-26 |
| DE3812194C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1990-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE19936428B4 (de) | Eisenionen enthaltendes Bakterizid | |
| DE69504037T2 (de) | Antivirale oder antifungale zusammensetzung und verfahren | |
| Tobias et al. | Antibacterial activity of dental restorative materials | |
| Podbielski et al. | Growth inhibitory activity of gutta-percha points containing root canal medications on common endodontic bacterial pathogens as determined by an optimized quantitative in vitro assay | |
| Jones | The effect of temperature, solids content and pH on the survival of salmonellas in cattle slurry | |
| DD268481A5 (de) | Pruefmittel und verfahren zur bestimmung von antibiotika in milch und dabei zu benutzender, neuer stamm von streptococcus thermophilus | |
| EP2103308A1 (de) | Verfahren zur Herstellung eines Gemisches von Bakteriophagen und deren Verwendung für die Therapie von Antibiotika-resistenten Staphylococcen | |
| DE2657150A1 (de) | Verfahren und vorrichtung zum nachweis von mikroorganismen | |
| DE3782214T2 (de) | Mittel zur behandlung des scheidenmilieus. | |
| BRPI0721035A2 (pt) | Soluções de armazenamento de meios cromatográficos e de equipamento cromatográfico e uso das mesmas. | |
| DE2615362A1 (de) | Verfahren und vorrichtung zum transportieren und aufbewahren von anaerobischen mikroorganismen | |
| DE3205018A1 (de) | Bifidobakterien vermehrendes mittel | |
| Marshall et al. | The bacteriological and clinical assessment of a new preparation for the treatment of otitis externa in dogs and cats | |
| DE3812194C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE2829316A1 (de) | Verfahren zum nachweis und zur untersuchung von zellulaerer aktivitaet und mittel zur durchfuehrung des verfahrens | |
| CS196370B2 (en) | Fodder admixture | |
| Kronman et al. | Microbiologic evaluation of poly-HEMA root canal filling material | |
| EP0569623B1 (de) | Mikroorganismenhaltiges Kulturlyophilisat mit vermehrungsfähigen Keimen, Verfahren zu seiner Herstellung und seine Verwendung | |
| Karlovic et al. | Antibacterial activity of halothane, eucalyptol and orange oil | |
| AKSU et al. | The possibilities for the use of commercial starter cultures in pastırma production | |
| DE10325404B4 (de) | Wässriges Suspensionsmedium mit lebensfähigen Milchsäurebakterien für probiotische Anwendungen | |
| Setiarso et al. | Production standardization of hand sanitizer spray based on ethanol, isopropanol, and bioethanol to prevent the COVID-19 transmission | |
| DE2212573C3 (de) | Prüfmittel zur halbquantitativen Bestimmung der in einer Flüssigkeit enthaltenen Mikroorganismen | |
| DE3505311C2 (de) | Selektives Mittel für Streptokokken der Gruppe A. | |
| Paramita et al. | Formulation and development of clove and coriander combination herbal dental anticaries gel and evaluation of its antimicrobial activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU DK FI HU JP SU US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |